"Prof. Sarah Coupland and Dr Joseph Sacco of the Liverpool Ocular Oncology Research Group (LOORG; www.loorg.org) are thrilled to share that the Uveal Melanoma 2022 treatment guidelines, executive summary, care pathway, appendices, slide set, full comments and replies and information for patients and carers are now published on the Melanoma Focus website.
https://melanomafocus.org/for-professionals/rare-melanoma-guidelines-and-consultations/uveal-melanoma-guidelines/
This work was undertaken by a Guideline Development Group (GDG) of 12 people from fields of medical oncology, clinical oncology, radiology, pathology, uveal melanoma science and patient representation and a project manager, over the last 2 years.
The lead of the GDG, Dr Paul Nathan states: “The Uveal Melanoma National Guidelines have recommended standards of care for all of our patients across the UK. These updated guidelines include recent advances in our understanding of the distinct biology of this disease, assess the evidence for recent improvements in care and have a renewed focus on patient experience. We believe they will continue to be an important reference document for patients, their supporters and clinicians."
https://melanomafocus.org/for-professionals/rare-melanoma-guidelines-and-consultations/uveal-melanoma-guidelines/
This work was undertaken by a Guideline Development Group (GDG) of 12 people from fields of medical oncology, clinical oncology, radiology, pathology, uveal melanoma science and patient representation and a project manager, over the last 2 years.
The lead of the GDG, Dr Paul Nathan states: “The Uveal Melanoma National Guidelines have recommended standards of care for all of our patients across the UK. These updated guidelines include recent advances in our understanding of the distinct biology of this disease, assess the evidence for recent improvements in care and have a renewed focus on patient experience. We believe they will continue to be an important reference document for patients, their supporters and clinicians."
